Latest Pharma Insights
Newron Confident In Evenamide Despite FDA Hold
The company updated investors on the status of evenamide development for schizophrenia as the US FDA investigates four deaths in the trial.
Scrip - October 8, 2026
The company updated investors on the status of evenamide development for schizophrenia as the US FDA investigates four deaths in the trial.
Scrip - October 8, 2026
Execs On The Move: September 28–October 2, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - October 8, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - October 8, 2026
Executives On The Move: Compass Pathways Adds A New Chief People Officer Ahead Of First Launch
Among other executive moves is Bayer naming Christoph Koenen as chief medical officer while he keeps his clinical development and operations role.
Scrip - October 8, 2026
Among other executive moves is Bayer naming Christoph Koenen as chief medical officer while he keeps his clinical development and operations role.
Scrip - October 8, 2026
AESGP Switch Day: Too Much Focus On Risk In Rx-To-OTC Reclassification Decisions
Former US FDA advisory committee chair Eric Brass told the AESGP switch conference in Brussels that switch decisions focus too much on risk, citing emergency contraception in Germany and heartburn drugs in the US as examples of the benefits at stake.
HBW Insight - October 8, 2026
Former US FDA advisory committee chair Eric Brass told the AESGP switch conference in Brussels that switch decisions focus too much on risk, citing emergency contraception in Germany and heartburn drugs in the US as examples of the benefits at stake.
HBW Insight - October 8, 2026
People On The Move: Appointments At Schwabe Group, Stada, Venture Life
A round-up of the latest moves in Europe's consumer health sector: Schwabe Group names chief commercial officer; Stada appoints global AI and digital leader; Venture Life names successor to CEO Jerry Randall.
HBW Insight - October 8, 2026
A round-up of the latest moves in Europe's consumer health sector: Schwabe Group names chief commercial officer; Stada appoints global AI and digital leader; Venture Life names successor to CEO Jerry Randall.
HBW Insight - October 8, 2026
Alvotech Broadens US Supply Footprint With Lotte Tie-Up
Marking another step in broadening its manufacturing network, Alvotech has announced a long-term partnership with Lotte Biologics that will see the firm produce drug substance for multiple antibody biosimilars at its US facilities in Syracuse, New York.
Generics Bulletin - October 8, 2026
Marking another step in broadening its manufacturing network, Alvotech has announced a long-term partnership with Lotte Biologics that will see the firm produce drug substance for multiple antibody biosimilars at its US facilities in Syracuse, New York.
Generics Bulletin - October 8, 2026
Argenx’s Celiac Win, Sjögren’s Setback Put Autoimmune Pipeline In Focus
The divergent readouts give argenx a new late-stage celiac contender even as the setback in Sjögren’s removes one of the key planned expansions for its flagship FcRn franchise.
Scrip - October 8, 2026
The divergent readouts give argenx a new late-stage celiac contender even as the setback in Sjögren’s removes one of the key planned expansions for its flagship FcRn franchise.
Scrip - October 8, 2026
German Medtechs’ 10-Point Plan Augurs ‘Autumn Of Reform’
BVMed set out its priorities for the government’s Medtech Dialog and growth strategy for industry against a backdrop of persistently weak annual performances amid a claimed fall in medtech company numbers.
Medtech Insight - October 8, 2026
BVMed set out its priorities for the government’s Medtech Dialog and growth strategy for industry against a backdrop of persistently weak annual performances amid a claimed fall in medtech company numbers.
Medtech Insight - October 8, 2026
Zealand Still Banking On Petrelintide’s Tolerability After Mixed T2D Results
Analysts see a role for the amylin agonist thanks to placebo-like tolerability, but Lilly and Novo candidates in the class will provide strong competition.
Scrip - October 8, 2026
Analysts see a role for the amylin agonist thanks to placebo-like tolerability, but Lilly and Novo candidates in the class will provide strong competition.
Scrip - October 8, 2026
Bayer Maintains Kerendia Momentum With Fourth US Filing
The German group is hoping to get the green light for the mineralocorticoid receptor antagonist for adults with chronic kidney disease without diabetes based on data from the FIND-CKD study.
Scrip - October 8, 2026
The German group is hoping to get the green light for the mineralocorticoid receptor antagonist for adults with chronic kidney disease without diabetes based on data from the FIND-CKD study.
Scrip - October 8, 2026
Kamada Expands Biosimilar Portfolio With Stelara And Clexane Rival Launches In Israel
Kamada has launched ustekinumab and enoxaparin biosimilars in Israel, though its current $10m 2028 revenue target is significantly below the $40m peak it projected in 2022.
Generics Bulletin - October 8, 2026
Kamada has launched ustekinumab and enoxaparin biosimilars in Israel, though its current $10m 2028 revenue target is significantly below the $40m peak it projected in 2022.
Generics Bulletin - October 8, 2026
Desai Takes Aim At Canadian Biosimilars With Launch Of Palindrome Pharma
Former Apotex chief executive Jeremy Desai is launching a new Canadian biosimilars company under the banner of Palindrome Pharma.
Generics Bulletin - October 8, 2026
Former Apotex chief executive Jeremy Desai is launching a new Canadian biosimilars company under the banner of Palindrome Pharma.
Generics Bulletin - October 8, 2026
First Devices Selected For EU Joint Assessment Process That Has Faced Pharma Skepticism
Edwards and Highlife’s mitral valve replacement systems will receive health technology assessment (HTA) at an EU level via a process designed for high-risk devices that can address unmet needs.
Medtech Insight - October 8, 2026
Edwards and Highlife’s mitral valve replacement systems will receive health technology assessment (HTA) at an EU level via a process designed for high-risk devices that can address unmet needs.
Medtech Insight - October 8, 2026
Newron Confident In Evenamide Despite FDA Hold
The company updated investors on the status of evenamide development for schizophrenia as the US FDA investigates four deaths in the trial.
Scrip - October 8, 2026
The company updated investors on the status of evenamide development for schizophrenia as the US FDA investigates four deaths in the trial.
Scrip - October 8, 2026
Executives On The Move: Compass Pathways Adds A New Chief People Officer Ahead Of First Launch
Among other executive moves is Bayer naming Christoph Koenen as chief medical officer while he keeps his clinical development and operations role.
Scrip - October 8, 2026
Among other executive moves is Bayer naming Christoph Koenen as chief medical officer while he keeps his clinical development and operations role.
Scrip - October 8, 2026
Argenx’s Celiac Win, Sjögren’s Setback Put Autoimmune Pipeline In Focus
The divergent readouts give argenx a new late-stage celiac contender even as the setback in Sjögren’s removes one of the key planned expansions for its flagship FcRn franchise.
Scrip - October 8, 2026
The divergent readouts give argenx a new late-stage celiac contender even as the setback in Sjögren’s removes one of the key planned expansions for its flagship FcRn franchise.
Scrip - October 8, 2026
Zealand Still Banking On Petrelintide’s Tolerability After Mixed T2D Results
Analysts see a role for the amylin agonist thanks to placebo-like tolerability, but Lilly and Novo candidates in the class will provide strong competition.
Scrip - October 8, 2026
Analysts see a role for the amylin agonist thanks to placebo-like tolerability, but Lilly and Novo candidates in the class will provide strong competition.
Scrip - October 8, 2026
Bayer Maintains Kerendia Momentum With Fourth US Filing
The German group is hoping to get the green light for the mineralocorticoid receptor antagonist for adults with chronic kidney disease without diabetes based on data from the FIND-CKD study.
Scrip - October 8, 2026
The German group is hoping to get the green light for the mineralocorticoid receptor antagonist for adults with chronic kidney disease without diabetes based on data from the FIND-CKD study.
Scrip - October 8, 2026
Execs On The Move: September 28–October 2, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - October 8, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - October 8, 2026
German Medtechs’ 10-Point Plan Augurs ‘Autumn Of Reform’
BVMed set out its priorities for the government’s Medtech Dialog and growth strategy for industry against a backdrop of persistently weak annual performances amid a claimed fall in medtech company numbers.
Medtech Insight - October 8, 2026
BVMed set out its priorities for the government’s Medtech Dialog and growth strategy for industry against a backdrop of persistently weak annual performances amid a claimed fall in medtech company numbers.
Medtech Insight - October 8, 2026
First Devices Selected For EU Joint Assessment Process That Has Faced Pharma Skepticism
Edwards and Highlife’s mitral valve replacement systems will receive health technology assessment (HTA) at an EU level via a process designed for high-risk devices that can address unmet needs.
Medtech Insight - October 8, 2026
Edwards and Highlife’s mitral valve replacement systems will receive health technology assessment (HTA) at an EU level via a process designed for high-risk devices that can address unmet needs.
Medtech Insight - October 8, 2026
AESGP Switch Day: Too Much Focus On Risk In Rx-To-OTC Reclassification Decisions
Former US FDA advisory committee chair Eric Brass told the AESGP switch conference in Brussels that switch decisions focus too much on risk, citing emergency contraception in Germany and heartburn drugs in the US as examples of the benefits at stake.
HBW Insight - October 8, 2026
Former US FDA advisory committee chair Eric Brass told the AESGP switch conference in Brussels that switch decisions focus too much on risk, citing emergency contraception in Germany and heartburn drugs in the US as examples of the benefits at stake.
HBW Insight - October 8, 2026
People On The Move: Appointments At Schwabe Group, Stada, Venture Life
A round-up of the latest moves in Europe's consumer health sector: Schwabe Group names chief commercial officer; Stada appoints global AI and digital leader; Venture Life names successor to CEO Jerry Randall.
HBW Insight - October 8, 2026
A round-up of the latest moves in Europe's consumer health sector: Schwabe Group names chief commercial officer; Stada appoints global AI and digital leader; Venture Life names successor to CEO Jerry Randall.
HBW Insight - October 8, 2026
Alvotech Broadens US Supply Footprint With Lotte Tie-Up
Marking another step in broadening its manufacturing network, Alvotech has announced a long-term partnership with Lotte Biologics that will see the firm produce drug substance for multiple antibody biosimilars at its US facilities in Syracuse, New York.
Generics Bulletin - October 8, 2026
Marking another step in broadening its manufacturing network, Alvotech has announced a long-term partnership with Lotte Biologics that will see the firm produce drug substance for multiple antibody biosimilars at its US facilities in Syracuse, New York.
Generics Bulletin - October 8, 2026
Kamada Expands Biosimilar Portfolio With Stelara And Clexane Rival Launches In Israel
Kamada has launched ustekinumab and enoxaparin biosimilars in Israel, though its current $10m 2028 revenue target is significantly below the $40m peak it projected in 2022.
Generics Bulletin - October 8, 2026
Kamada has launched ustekinumab and enoxaparin biosimilars in Israel, though its current $10m 2028 revenue target is significantly below the $40m peak it projected in 2022.
Generics Bulletin - October 8, 2026
Desai Takes Aim At Canadian Biosimilars With Launch Of Palindrome Pharma
Former Apotex chief executive Jeremy Desai is launching a new Canadian biosimilars company under the banner of Palindrome Pharma.
Generics Bulletin - October 8, 2026
Former Apotex chief executive Jeremy Desai is launching a new Canadian biosimilars company under the banner of Palindrome Pharma.
Generics Bulletin - October 8, 2026
Rare To Blockbuster: Expansion Strategies In Non-Oncology Precision Medicine
Setmelanotide grew from $3m to $195m in annual sales by stretching one mechanism across rare and acquired obesity, and a handful of non-oncology precision medicines in the pipeline are now attempting the same trick on far larger patient populations.
In Vivo - October 7, 2026
Setmelanotide grew from $3m to $195m in annual sales by stretching one mechanism across rare and acquired obesity, and a handful of non-oncology precision medicines in the pipeline are now attempting the same trick on far larger patient populations.
In Vivo - October 7, 2026
MIT’s Barzilay Wants AI To Predict Who Responds
Since her 2014 breast cancer diagnosis, MIT's Regina Barzilay has built artificial intelligence tools for screening and drug discovery. Now she is developing AI to predict which patients will respond to which treatments.
In Vivo - October 7, 2026
Since her 2014 breast cancer diagnosis, MIT's Regina Barzilay has built artificial intelligence tools for screening and drug discovery. Now she is developing AI to predict which patients will respond to which treatments.
In Vivo - October 7, 2026